Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: codiakbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/22/2022 | $34.00 → $24.00 | Outperform | Wedbush |
| 2/11/2022 | $19.00 | Buy | Goldman Sachs |
25-NSE - Codiak BioSciences, Inc. (0001659352) (Subject)
NT 10-K - Codiak BioSciences, Inc. (0001659352) (Filer)
8-K - Codiak BioSciences, Inc. (0001659352) (Filer)
10-Q - Codiak BioSciences, Inc. (0001659352) (Filer)
8-K - Codiak BioSciences, Inc. (0001659352) (Filer)
8-K - Codiak BioSciences, Inc. (0001659352) (Filer)
424B5 - Codiak BioSciences, Inc. (0001659352) (Filer)
424B5 - Codiak BioSciences, Inc. (0001659352) (Filer)
8-K - Codiak BioSciences, Inc. (0001659352) (Filer)
10-Q - Codiak BioSciences, Inc. (0001659352) (Filer)
Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously
Goldman Sachs initiated coverage of Codiak BioSciences with a rating of Buy and set a new price target of $19.00